Skip to main content
Reveal menu for sighted


Prof. Mario A. Monteiro

Vaccine Research Laboratory
Prof. Mario Monteiro
Department of Chemistry
University of Guelph
Guelph, Ontario, N1G 2W1

News & Events

Speaker at Instituto Superior Tecnico 2017 ChemForum in Lisbon
Dr. Silvia Borrelli: 19th European Carbohydrate Symposium in Spain
Dr. Silvia Borrelli presents our most advanced vaccine research at the 19th European Carbohydrate Symposium in Spain. Silvia will describe our vaccines against the gastric pathogens Clostridium difficile and Campylobacter jejuni.
Dr. Silvia Borrelli: 19th European Carbohydrate Symposium in Spain

The challenges of taking lab concepts to commercialization were the focus of a Talk Local Guelph interview April 4. The show will air several times this week. Physics professor John Dutcher, chemistry professor Mario Monteiro, and Catalyst Centre staff members David Hobson and Steve de Brabandere explained the complicated path to take an idea to market. …
Feature article about our research
He never quite leaves the chemistry lab behind. Even as he heads home each day, part of Prof. Mario Monteiro remains in U of G’s MacNaughton Building with his studies of carbohydrate-based vaccines. And that part of him is still there the next morning. “I do wake up thinking about the research,” he says. “It’s not like I close the door.” 
The tuberculosis (TB) vaccine hasn’t changed much since it was first used on humans almost a century ago, yet the disease is still prevalent in Canada’s aboriginal communities and in developing countries.
“It’s not effective anymore, especially in adults,” says University of Guelph chemistry professor Mario Monteiro. “It’s not even used now in North America.”
Monteiro is working on a new — and hopefully more effective — type of TB vaccine that uses a plant-based ingredient to trigger an immune response in the body.
Recipient of the University of Guelph Inaugural Innovation Award
Prof. Mario Monteiro receiving the University of Guelph Inaugural Innovation Award
[Said University of Guelph vice-president research Malcolm Campbell,] “Prof. Monteiro’s research led to the world’s first glycoconjugate vaccine that may be capable of controlling both infection and colonization levels from C. difficile."
(developed by Kristina Salciccioli)
Prof. Mario Monteiro
Carbohydrate chemist Mario Monteiro develops vaccines to thwart pathogenic bacteria. His latest challenge may be his biggest yet — creating a vaccine to fight the gastric bugs that cause havoc in the lives of autistic children.